Ampliphi Biosciences Corp (NYSEAMERICAN:APHB – Get Free Report) rose 9.3% during trading on Wednesday . The stock traded as high as $9.59 and last traded at $9.54. Approximately 133,273 shares changed hands during trading, a decline of 84% from the average daily volume of 842,200 shares. The stock had previously closed at $8.73.
Ampliphi Biosciences Stock Performance
The firm’s 50-day simple moving average is $6.96 and its 200-day simple moving average is $5.17.
Ampliphi Biosciences Company Profile
Ampliphi Biosciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of novel therapies to prevent and treat life‐threatening drug‐resistant infections. The company’s core mission is to address the growing global threat of antibiotic resistance by advancing first‐in‐class and best‐in‐class antibacterial agents through late‐stage clinical trials.
The company’s lead product candidate, exeporfinium chloride (XF-73), is a pioneering topical antibacterial designed for pre‐operative nasal decolonization of Staphylococcus aureus in patients undergoing high‐risk surgical procedures.
Read More
- Five stocks we like better than Ampliphi Biosciences
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- This makes me furious
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
